Yoshihiro Nishita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yoshihiro Nishita has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Masatoshi Taga
Department of Pharmacy, Kanazawa Medical University Hospital, 1-1 Daigaku, Uchinada-cho, Kahoku-gun, Ishikawa 920-0293, Japan
5 shared publicationsTogen Masauji
Department of Pharmacy, Kanazawa Medical University Hospital, 1-1 Daigaku, Uchinada-cho, Kahoku-gun, Ishikawa 920-0293, Japan
5 shared publicationsYoshitsugu Iinuma
Department of Infectious Disease, Kanazawa Medical University, 1-1 Daigaku, Uchinada-cho, Kahoku-gun, Ishikawa 920-0293, Japan
4 shared publicationsJunko Ishizaki
Clinical Pharmacy and Healthcare Science, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan
2 shared publicationsMasaru Sakurai
Department of Social and Environmental Medicine, Kanazawa Medical University, Kahoku-gun, Japan
2 shared publicationsNatsuko Ishida
Clinical Pharmacy and Healthcare Science, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan
2 shared publications
Latest Publications
- 19 December 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (1) , 102898
The effect of pharmacist-led antimicrobial stewardship on antimicrobial use in an intensive care unit: a single-center, retrospective, observational study
- 19 December 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (1) , 102898
The effect of pharmacist-led antimicrobial stewardship on antimicrobial use in an intensive care unit: a single-center, retrospective, observational study
- Open Access
- 27 June 2025
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 39 (4) , 2320-2327
Risk Factors Associated With Thrombocytopenia Induced by Intravenous Immunoglobulin Formulations: An Analysis Using the JADER database
Thrombocytopenia is a serious adverse event observed with intravenous immunoglobulin formulations (IVIg). There have been some individual case reports of such events, but to our knowledge, no epidemiological studies have been reported. In this study, the risk of IVIg-induced thrombocytopenia and factors associated with IVIg-induced thrombocytopenia were examined using the Japanese Adverse Drug Event Report database. Data spanning from April 2004 to August 2024 were used. The association between IVIg and thrombocytopenia was evaluated using the reporting odds ratio (ROR). The reports of IVIg-induced thrombocytopenia events were evaluated by disease and aggregated by disease group. Factors associated with IVIg-induced thrombocytopenia were detected using multiple logistic regression with age, sex, formulation method, and disease group as explanatory variables and adjusted RORs were calculated. The IVIgs examined were significantly associated with thrombocytopenia. Pemphigoid was the most frequently reported disease, followed by Kawasaki disease and polymyositis/dermatomyositis. Immune-mediated skin diseases were the most frequently reported disease group, followed by Kawasaki disease, immune-mediated neurological diseases, and immune-mediated muscular diseases. Multiple logistic regression analysis showed that at age 60 years or older, immune-mediated skin diseases and immune-mediated muscular diseases were independently associated with significantly increased RORs. This study suggests that IVIg can induce thrombocytopenia and that thrombocytopenia should be assessed in patients with immune-mediated skin diseases, immune-mediated muscular diseases and in the elderly.
- 27 June 2025
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 39 (4) , 2320-2327
Open AccessRisk Factors Associated With Thrombocytopenia Induced by Intravenous Immunoglobulin Formulations: An Analysis Using the JADER database
Thrombocytopenia is a serious adverse event observed with intravenous immunoglobulin formulations (IVIg). There have been some individual case reports of such events, but to our knowledge, no epidemiological studies have been reported. In this study, the risk of IVIg-induced thrombocytopenia and factors associated with IVIg-induced thrombocytopenia were examined using the Japanese Adverse Drug Event Report database. Data spanning from April 2004 to August 2024 were used. The association between IVIg and thrombocytopenia was evaluated using the reporting odds ratio (ROR). The reports of IVIg-induced thrombocytopenia events were evaluated by disease and aggregated by disease group. Factors associated with IVIg-induced thrombocytopenia were detected using multiple logistic regression with age, sex, formulation method, and disease group as explanatory variables and adjusted RORs were calculated. The IVIgs examined were significantly associated with thrombocytopenia. Pemphigoid was the most frequently reported disease, followed by Kawasaki disease and polymyositis/dermatomyositis. Immune-mediated skin diseases were the most frequently reported disease group, followed by Kawasaki disease, immune-mediated neurological diseases, and immune-mediated muscular diseases. Multiple logistic regression analysis showed that at age 60 years or older, immune-mediated skin diseases and immune-mediated muscular diseases were independently associated with significantly increased RORs. This study suggests that IVIg can induce thrombocytopenia and that thrombocytopenia should be assessed in patients with immune-mediated skin diseases, immune-mediated muscular diseases and in the elderly.
- Open Access
Strategies to Maximize the Benefits of Evidence-Based Enteral Nutrition: A Narrative Review
Enteral nutrition (EN) has been reported to have some physiological importance for critically ill patients. However, the advantage of EN over parenteral nutrition remains controversial in recent paradigms. To maximize the benefits and efficiency of EN, implementing measures based on comprehensive evidence is essential. Here, we systematically reviewed EN-related studies and integrated them into the best and most up-to-date EN practices. We extracted studies from 13 systematic reviews during the development of Japanese Critical Care Nutrition Guidelines, summarizing findings on the assessment of enteral feeding intolerance (EFI), the timing of EN, formula composition and nutrients, and method of administration in critically ill adult patients. Multifaceted EFI assessment may be needed in patients for high-risk patients. Early EN may reduce infectious complications, and initiating EN even earlier may offer an additional advantage. High protein intake (≥1.2 g/kg/day) could maintain muscle mass and physical function without increasing gastrointestinal complications. Probiotics, prebiotics, and synbiotics may serve as beneficial options for preventing infection and gastrointestinal complications, although their efficacy depends on the strains, types, and combinations used. For patients with EFI, post-pyloric feeding could be an effective approach, while intermittent feeding may be a safer approach. Both methods should be utilized to achieve nutritional targets. Integrating these nutritional interventions into EN strategies may help maximize their effectiveness and minimize complications. However, careful consideration regarding timing, dosage, nutrient selection, administration methods, and patient selection is required.
Open AccessStrategies to Maximize the Benefits of Evidence-Based Enteral Nutrition: A Narrative Review
Enteral nutrition (EN) has been reported to have some physiological importance for critically ill patients. However, the advantage of EN over parenteral nutrition remains controversial in recent paradigms. To maximize the benefits and efficiency of EN, implementing measures based on comprehensive evidence is essential. Here, we systematically reviewed EN-related studies and integrated them into the best and most up-to-date EN practices. We extracted studies from 13 systematic reviews during the development of Japanese Critical Care Nutrition Guidelines, summarizing findings on the assessment of enteral feeding intolerance (EFI), the timing of EN, formula composition and nutrients, and method of administration in critically ill adult patients. Multifaceted EFI assessment may be needed in patients for high-risk patients. Early EN may reduce infectious complications, and initiating EN even earlier may offer an additional advantage. High protein intake (≥1.2 g/kg/day) could maintain muscle mass and physical function without increasing gastrointestinal complications. Probiotics, prebiotics, and synbiotics may serve as beneficial options for preventing infection and gastrointestinal complications, although their efficacy depends on the strains, types, and combinations used. For patients with EFI, post-pyloric feeding could be an effective approach, while intermittent feeding may be a safer approach. Both methods should be utilized to achieve nutritional targets. Integrating these nutritional interventions into EN strategies may help maximize their effectiveness and minimize complications. However, careful consideration regarding timing, dosage, nutrient selection, administration methods, and patient selection is required.
- Open Access
- 28 January 2025
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 11 (1) , 1-5
Toxic epidermal necrolysis with thrombocytopenia induced by intravenous immunoglobulin: a case report and mini review
Background: Toxic epidermal necrolysis (TEN), a severe cutaneous hypersensitivity reaction induced particularly by drugs, is diagnosed when there is a fever of ≥ 38 °C, mucocutaneous symptoms, a rash with multiple erythema, and skin peeling of ≥ 30% of the body surface area. The mortality rate of TEN is high, and thrombocytopenia during treatment can lead to severe outcomes. Intravenous immunoglobulin (IVIg) is used when steroids are ineffective in TEN and may improve mortality; however, thrombocytopenia is a rare adverse event associated with IVIg use. We report the case of thrombocytopenia during IVIg therapy for TEN. We also reviewed previous reports to learn more about the clinical course and mechanism of IVIg-induced thrombocytopenia. Case presentation: An 83-year-old man with end-stage renal failure on hemodialysis was diagnosed with TEN. After an inadequate response to pulse methylprednisolone therapy, IVIg (400 mg/kg/day) was administered for 5 days. He developed thrombocytopenia after IVIg administration, leading to the diagnosis of thrombocytopenia due to IVIg after excluding other diseases. The platelet count began to increase approximately 10 days after IVIg administration. Conclusions: When IVIg is administered for TEN, the risk of thrombocytopenia should be recognized and the platelet count should be carefully monitored.
- 28 January 2025
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 11 (1) , 1-5
Open AccessToxic epidermal necrolysis with thrombocytopenia induced by intravenous immunoglobulin: a case report and mini review
Background: Toxic epidermal necrolysis (TEN), a severe cutaneous hypersensitivity reaction induced particularly by drugs, is diagnosed when there is a fever of ≥ 38 °C, mucocutaneous symptoms, a rash with multiple erythema, and skin peeling of ≥ 30% of the body surface area. The mortality rate of TEN is high, and thrombocytopenia during treatment can lead to severe outcomes. Intravenous immunoglobulin (IVIg) is used when steroids are ineffective in TEN and may improve mortality; however, thrombocytopenia is a rare adverse event associated with IVIg use. We report the case of thrombocytopenia during IVIg therapy for TEN. We also reviewed previous reports to learn more about the clinical course and mechanism of IVIg-induced thrombocytopenia. Case presentation: An 83-year-old man with end-stage renal failure on hemodialysis was diagnosed with TEN. After an inadequate response to pulse methylprednisolone therapy, IVIg (400 mg/kg/day) was administered for 5 days. He developed thrombocytopenia after IVIg administration, leading to the diagnosis of thrombocytopenia due to IVIg after excluding other diseases. The platelet count began to increase approximately 10 days after IVIg administration. Conclusions: When IVIg is administered for TEN, the risk of thrombocytopenia should be recognized and the platelet count should be carefully monitored.
- Open Access
- 12 December 2022
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 8 (1) , 1-10
Prognostic factors in patients with septic disseminated intravascular coagulation treated with thrombomodulin: the effect of reduced thrombomodulin dose; a single-center, retrospective, observational study
Human soluble recombinant thrombomodulin (TM alfa), a treatment for septic Disseminated intravascular coagulation (DIC), is recommended for patients with severe renal dysfunction in reduced doses. However, no studies have examined yet how dose reduction affects clinical efficacy. In this study, we investigated the significance of the TM alfa dose as a prognostic factor in clarifying the clinical background factors related to the clinical effect of TM alfa in patients with septic DIC. This study involved 102 patients with septic DIC admitted to a single-center intensive care unit between April 2013 and March 2020, receiving TM alfa. The following factors were retrospectively collected from the medical records of the target patients: (1) patient background, (2) sequential organ failure assessment (SOFA) score, (3) Japanese Association for Acute Medicine DIC diagnostic criteria score, (4) DIC treatment information, (5) TM alfa dose per bodyweight (normal dose: 0.06 mg/kg or reduced dose: 0.02 mg/kg), (6) DIC resolution within 7 days after the start of TM alfa administration (DIC resolution), (7) all deaths within 30 days after the start of TM alfa administration (30-days-all-cause mortality), (8) presence or absence of new hemorrhagic side effects after the start of TM alfa administration. Multiple logistic regression analysis was used to assess factors associated with DIC resolution and 30-days-all-cause mortality. The SOFA score (odds ratio: 95% confidence interval, 0.76: 0.66–0.89), pneumonia (0.24: 0.08–0.75), and reduced dose administration of TM alfa (0.23: 0.08–0.66) were independent of and negatively related to the DIC resolution. For the 30-days-all-cause mortality, the SOFA score (1.66: 1.31–2.09), pneumonia (9.50: 2.49–36.25), and TM alfa dose reduction (3.52: 1.06–11.69) were independent, poor prognostic factors. We found no association between the hemorrhagic side effects and the TM alfa dose per bodyweight. The reduced dose of TM alfa for patients with severe renal dysfunction was observed to be an influential factor for DIC resolution and 30-day all-cause mortality, as were SOFA scores and pneumonia. Further studies are required in the future to verify this finding.
- 12 December 2022
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 8 (1) , 1-10
Open AccessPrognostic factors in patients with septic disseminated intravascular coagulation treated with thrombomodulin: the effect of reduced thrombomodulin dose; a single-center, retrospective, observational study
Human soluble recombinant thrombomodulin (TM alfa), a treatment for septic Disseminated intravascular coagulation (DIC), is recommended for patients with severe renal dysfunction in reduced doses. However, no studies have examined yet how dose reduction affects clinical efficacy. In this study, we investigated the significance of the TM alfa dose as a prognostic factor in clarifying the clinical background factors related to the clinical effect of TM alfa in patients with septic DIC. This study involved 102 patients with septic DIC admitted to a single-center intensive care unit between April 2013 and March 2020, receiving TM alfa. The following factors were retrospectively collected from the medical records of the target patients: (1) patient background, (2) sequential organ failure assessment (SOFA) score, (3) Japanese Association for Acute Medicine DIC diagnostic criteria score, (4) DIC treatment information, (5) TM alfa dose per bodyweight (normal dose: 0.06 mg/kg or reduced dose: 0.02 mg/kg), (6) DIC resolution within 7 days after the start of TM alfa administration (DIC resolution), (7) all deaths within 30 days after the start of TM alfa administration (30-days-all-cause mortality), (8) presence or absence of new hemorrhagic side effects after the start of TM alfa administration. Multiple logistic regression analysis was used to assess factors associated with DIC resolution and 30-days-all-cause mortality. The SOFA score (odds ratio: 95% confidence interval, 0.76: 0.66–0.89), pneumonia (0.24: 0.08–0.75), and reduced dose administration of TM alfa (0.23: 0.08–0.66) were independent of and negatively related to the DIC resolution. For the 30-days-all-cause mortality, the SOFA score (1.66: 1.31–2.09), pneumonia (9.50: 2.49–36.25), and TM alfa dose reduction (3.52: 1.06–11.69) were independent, poor prognostic factors. We found no association between the hemorrhagic side effects and the TM alfa dose per bodyweight. The reduced dose of TM alfa for patients with severe renal dysfunction was observed to be an influential factor for DIC resolution and 30-day all-cause mortality, as were SOFA scores and pneumonia. Further studies are required in the future to verify this finding.
- Open Access
- 28 January 2022
- Published by Springer Nature in Research Square
Prognostic factors in patients with septic disseminated intravascular coagulation treated with thrombomodulin: the effect of reduced thrombomodulin dose; a single-center, retrospective, observational study
Background: Human soluble recombinant thrombomodulin (TM alfa), a treatment for septic Disseminated intravascular coagulation (DIC), is recommended for patients with severe renal dysfunction in reduced doses. However, no studies have examined yet how dose reduction affects clinical efficacy. In this study, we investigated the significance of the TM alfa dose as a prognostic factor in clarifying the clinical background factors related to the clinical effect of TM alfa in patients with septic DIC.Methods: This study involved 102 patients with septic DIC admitted to a single-center intensive care unit between April 2013 and March 2020, receiving TM alfa. The following factors were retrospectively collected from the medical records of the target patients: (1) patient background, (2) sequential organ failure assessment (SOFA) score, (3) Japanese Association for Acute Medicine DIC diagnostic criteria score, (4) DIC treatment information, (5) TM alfa dose per bodyweight (normal dose: 0.06 mg/kg or reduced dose: 0.02 mg/kg), (6) DIC resolution within 7 days after the start of TM alfa administration (DIC resolution), (7) all deaths within 30 days after the start of TM alfa administration (30-days-all-cause mortality), (8) presence or absence of new hemorrhagic side effects after the start of TM alfa administration. Multiple logistic regression analysis was used to assess factors associated with DIC resolution and 30-days-all-cause mortality.Results: The SOFA score (odds ratio: 95% confidence interval, 0.76: 0.66–0.89), pneumonia (0.24: 0.08–0.75), and reduced dose administration of TM alfa (0.23: 0.08–0.66) were independent of and negatively related to the DIC resolution. For the 30-days-all-cause mortality, the SOFA score (1.66: 1.31–2.09), pneumonia (9.50: 2.49–36.25), and TM alfa dose reduction (3.52: 1.06–11.69) were independent, poor prognostic factors. We found no association between the hemorrhagic side effects and the TM alfa dose per bodyweight.Conclusions: The reduced dose of TM alfa for patients with severe renal dysfunction was observed to be an influential factor for DIC resolution and 30-day all-cause mortality in addition to SOFA score and pneumonia. Further studies are required in the future to verify this finding.
- 28 January 2022
- Published by Springer Nature in Research Square
Open AccessPrognostic factors in patients with septic disseminated intravascular coagulation treated with thrombomodulin: the effect of reduced thrombomodulin dose; a single-center, retrospective, observational study
Background: Human soluble recombinant thrombomodulin (TM alfa), a treatment for septic Disseminated intravascular coagulation (DIC), is recommended for patients with severe renal dysfunction in reduced doses. However, no studies have examined yet how dose reduction affects clinical efficacy. In this study, we investigated the significance of the TM alfa dose as a prognostic factor in clarifying the clinical background factors related to the clinical effect of TM alfa in patients with septic DIC.Methods: This study involved 102 patients with septic DIC admitted to a single-center intensive care unit between April 2013 and March 2020, receiving TM alfa. The following factors were retrospectively collected from the medical records of the target patients: (1) patient background, (2) sequential organ failure assessment (SOFA) score, (3) Japanese Association for Acute Medicine DIC diagnostic criteria score, (4) DIC treatment information, (5) TM alfa dose per bodyweight (normal dose: 0.06 mg/kg or reduced dose: 0.02 mg/kg), (6) DIC resolution within 7 days after the start of TM alfa administration (DIC resolution), (7) all deaths within 30 days after the start of TM alfa administration (30-days-all-cause mortality), (8) presence or absence of new hemorrhagic side effects after the start of TM alfa administration. Multiple logistic regression analysis was used to assess factors associated with DIC resolution and 30-days-all-cause mortality.Results: The SOFA score (odds ratio: 95% confidence interval, 0.76: 0.66–0.89), pneumonia (0.24: 0.08–0.75), and reduced dose administration of TM alfa (0.23: 0.08–0.66) were independent of and negatively related to the DIC resolution. For the 30-days-all-cause mortality, the SOFA score (1.66: 1.31–2.09), pneumonia (9.50: 2.49–36.25), and TM alfa dose reduction (3.52: 1.06–11.69) were independent, poor prognostic factors. We found no association between the hemorrhagic side effects and the TM alfa dose per bodyweight.Conclusions: The reduced dose of TM alfa for patients with severe renal dysfunction was observed to be an influential factor for DIC resolution and 30-day all-cause mortality in addition to SOFA score and pneumonia. Further studies are required in the future to verify this finding.
- Open Access
- 25 March 2019
- Published by Japanese Society of Environmental Infections in Japanese Journal of Infection Prevention and Control
- Vol. 34 (2) , 115-121
Feasibility and Value of Developing an Age-stratified Antibiogram
年齢層別化アンチバイオグラムの意義について検討を行った.2015年4月からの1年間に当院にて分離頻度が高かった黄色ブドウ球菌,肺炎球菌,インフルエンザ桿菌,大腸菌,緑膿菌を対象に,抗菌薬感性率を小児,非高齢成人,高齢成人で比較した.グラム陽性菌では,成人由来株との比較において小児由来のメチシリン感性黄色ブドウ球菌ではマクロライド低感受性,メチシリン耐性黄色ブドウ球菌ではレボフロキサシン(LVFX)およびミノサイクリンの高感受性が示され,肺炎球菌では髄膜炎基準で小児由来株のペニシリン低感受性が示された.非高齢成人と高齢成人では差はみられなかった.グラム陰性菌では,小児および高齢成人が非高齢成人よりも比較的感受性が低かった.特に大腸菌ではアンピシリン/スルバクタム,セフェム系抗菌薬,LVFX,ST合剤,ホスホマイシンの多系統の低感受性が認められた.臨床上問題となる耐性菌の分離率は非高齢成人が最も低く,小児および高齢成人における初期治療において注意が必要と考えられた.年齢層別化アンチバイオグラムの作成は特に小児,高齢成人の感染症の初期治療において重要と考えられた.
- 25 March 2019
- Published by Japanese Society of Environmental Infections in Japanese Journal of Infection Prevention and Control
- Vol. 34 (2) , 115-121
Open AccessFeasibility and Value of Developing an Age-stratified Antibiogram
年齢層別化アンチバイオグラムの意義について検討を行った.2015年4月からの1年間に当院にて分離頻度が高かった黄色ブドウ球菌,肺炎球菌,インフルエンザ桿菌,大腸菌,緑膿菌を対象に,抗菌薬感性率を小児,非高齢成人,高齢成人で比較した.グラム陽性菌では,成人由来株との比較において小児由来のメチシリン感性黄色ブドウ球菌ではマクロライド低感受性,メチシリン耐性黄色ブドウ球菌ではレボフロキサシン(LVFX)およびミノサイクリンの高感受性が示され,肺炎球菌では髄膜炎基準で小児由来株のペニシリン低感受性が示された.非高齢成人と高齢成人では差はみられなかった.グラム陰性菌では,小児および高齢成人が非高齢成人よりも比較的感受性が低かった.特に大腸菌ではアンピシリン/スルバクタム,セフェム系抗菌薬,LVFX,ST合剤,ホスホマイシンの多系統の低感受性が認められた.臨床上問題となる耐性菌の分離率は非高齢成人が最も低く,小児および高齢成人における初期治療において注意が必要と考えられた.年齢層別化アンチバイオグラムの作成は特に小児,高齢成人の感染症の初期治療において重要と考えられた.